

9805602-1
IPOS COPY



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/765, 9/127, 47/32 // (A61K 31/765, 31:00)	A1	(11) International Publication Number: WO 97/42962 (43) International Publication Date: 20 November 1997 (20.11.97)
(21) International Application Number: PCT/CA97/00319 (22) International Filing Date: 9 May 1997 (09.05.97) (30) Priority Data: 60/017,106 ☒ 9 May 1996 (09.05.96) ☒ US (71)(72) Applicants and Inventors: BERGERON, Michel, G. [CA/CA]; 2069 Brûlard, Sillery, Quebec G1T 1G2 (CA). DESORMEAUX, André [CA/CA]; 7640 de Beauchastel, Neufchatel, Quebec G2C 1Y1 (CA). TREMBLAY, Michel [CA/CA]; 7073 rue Des Brunes, Neufchatel, Quebec G2C 1P3 (CA). (74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FORMULATION FOR USE IN THE PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV (57) Abstract This invention relates to formulations comprising film-forming components capable of forming <i>per se</i> a physical barrier to pathogens. Thermoreversible gels such as poloxamers are particularly preferred for that use. The film-forming formulations may further comprise microbicides, spermicides or any other drug, which choice is guided by the pathogen, organism or the disease to be inactivated or treated. The formulations are therefore efficient as a physical, and optionally, as a chemical or pharmacological barrier as well as usable as a sustained drug-release system at the locus of administration. A part of the drug may also be entrapped in liposomes or other drug carriers. These formulations are intended for use in the prevention of sexually transmitted diseases, as well as in the treatment of infections, cancer, inflammation or any disease or state which requires a pharmacological treatment. Formulations are applicable to mucosae, skin and eye, for example.		